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Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heart muscle disorder char-
acterized by fibro-fatty replacement of cardiomyocytes. The cardinal manifestations are
arrhythmias, sudden cardiac death, and seldom heart failure. Mutations in genes encoding
desmosomal proteins and their interaction partners have been implicated in the pathogen-
esis of ARVC and it is now widely accepted that ARVC is a disease caused by abnormal
cell–cell adhesion. The mechanism(s) by which mutations in desmosomal proteins lead to
fibro-fatty replacement remains to be fully elucidated. To this aim over the last 10 years
different transgenic and targeted mouse models have been developed, these models and
what they have taught us will be discussed in this review.
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INTRODUCTION
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an
important cause of ventricular arrhythmias and sudden cardiac
death, especially in the young and in athletes (Marcus et al.,
1982; Thiene et al., 1988; Basso et al., 2009). Mutations in one
or more genes encoding desmosomal proteins are found in∼50%
of patients (McKoy et al., 2000; Rampazzo et al., 2002; Gerull
et al., 2004; Pilichou et al., 2006; Syrris et al., 2006). Desmo-
somes are highly conserved structures that, together with adherens
junctions and gap junctions, connect cardiac myocytes end to
end at the level of the intercalated disks and thereby play a
crucial role in maintaining proper myocardial function (Del-
mar and McKenna, 2010). Recent findings indicating the pres-
ence of mixed type junctions (the area composite; Franke et al.,
2006) and crosstalk between protein complexes pertaining to
the different types of junctions (Delmar, 2004; Meadows and
Isom, 2005; Saffitz, 2005; Tavora et al., 2009; Li and Radice,
2010; Sato et al., 2011) have markedly changed the perception
of the intercalated disk. Altered junctional organization, as the
result of mutations, is thought to lead to myocardial damage
and replacement fibrosis, the classical histopathologic pattern of
ARVC (Basso et al., 2009). In advanced stages of the disease,
focal scars cause electrical isolation of cardiomyocytes within
non-conducting fibrous tissue, resulting in slow conduction and
delayed activation, thus forming the substrate for re-entrant cir-
cuits and ventricular electrical instability. Over the years several
mouse models have been developed to investigate the mechanisms
of disease development in ARVC (Pilichou et al., 2011), focusing
on four of the desmosomal proteins: Plakophilin-2, Plakoglobin
(γ-catenin), Desmoplakin, and Desmoglein 2. All four will be dis-
cussed in detail below; an overview of all the models is given in
Table 1.
PLAKOPHILIN-2 TARGETED DELETION
The first mouse model described that addresses disruption of
one of the desmosomal proteins is the study by Grossmann et al.
(2004) that describes the targeted deletion of plakophilin-2. The
heterozygous mice carrying one wild type copy of plakophilin-
2 were completely viable without any cardiac phenotype. Mouse
homozygous for the deletion (Pkp2−/−) died during embryonic
development around day 11 post fertilization. Embryos at day 10.5
appeared pale with blood aggregates in the interperitoneal cavity
indicating the presence of small holes in the endothelial layers lin-
ing the heart and vessels. It would be interesting to see if the Pkp2±
mice develop an ARVC like phenotype upon exercise.
PLAKOGLOBIN TARGETED DELETION AND OVEREXPRESSION
MODELS
The first papers on mouse models involving a desmosomal protein
described the targeted deletion of Plakoglobin (Pg ) by two inde-
pendent groups in 1996 (models Pg1 and Pg2; Bierkamp et al.,
1996; Ruiz et al., 1996). Homozygous targeted deletion of Plako-
globin leads to embryonic lethality between embryonic day 9.5 and
16 due to cardiac malformations: thin cardiac walls and less tra-
beculation and frequent burst of the epicardial wall; in addition
mice showed a blistering skin phenotype. Heterozygous animals
appeared healthy and fertile. However, closer inspection of these
mice (model Pg2) after the link between ARVC and desmosomal
proteins had become clear showed that Pg± mice at 10 months
after birth had enlarged right ventricles, increased spontaneous
ventricular arrhythmias and right ventricular conduction slow-
ing. No replacement fibrosis and remodeling of the junctions
was observed, Cx43 localization and distribution were normal
on immunofluorescence microscopy. All observed changes were
exacerbated and expedited when mice were subjected to exercise
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Table 1 | Arrhythmogenic right ventricular cardiomyopathy mouse models.
Nr Protein Gene Mutation/targeted exons Model type Reference
Pk1 Plakophilin-2 Pkp2 Exon 1-intron 1 Targeted deletion Grossmann et al. (2004)
Pk2 Plakophilin-2 Pkp2 Exon 1-intron 1 Targeted deletion Grossmann et al. (2004)
Pg1 Plakoglobin Jup Exon 2–5 Targeted deletion Bierkamp et al. (1996)
Pg2–Pg4 Plakoglobin Jup Exon 34 Targeted deletion Ruiz et al. (1996), Kirchhof et al. (2006),
Fabritz et al. (2011)
Pg5 Plakoglobin Jup Exon 2–3 Inducible deletion; αMHCcre induced Li et al. (2011)
Pg6 Plakoglobin
β-catenin
Jup Exon 2–3 αMHC/MerCreMer tamoxifen induced
double deletion
Swope et al. (2012)
Ctnnb1 Exon 2–5
Pg7 Plakoglobin Jup Wild type Flag tagged transgene Lombardi et al. (2011)
Pg8 Plakoglobin Jup 23654∆2 Transgene Lombardi et al. (2011)
Truncated
Dp1 Desmoplakin Dsp ∆281–473 Targeted deletion with extra-embryonic
rescue
Gallicano et al. (2001)
Dp2 Desmoplakin Dsp Exon 2 Inducible deletion; αMHCcre induced Garcia-Gras et al. (2006), Gomes et al.
(2012)
Dp3 Desmoplakin Dsp Wild type Flag tagged transgene, αMHC promoter Yang et al. (2006)
Dp4 Desmoplakin Dsp R2834H Flag tagged transgene, αMHC promoter Yang et al. (2006)
Dp5 Desmoplakin Dsp Q90R Flag tagged transgene, αMHC promoter Yang et al. (2006)
Dp6 Desmoplakin Dsp V30M Flag tagged transgene, αMHC promoter Yang et al. (2006)
Dg1 Desmoglein 2 Dsg2 Wild type Flag tagged transgene, αMHC promoter Pilichou et al. (2009)
Dg2 Desmoglein 2 Dsg2 N271S Flag tagged transgene, αMHC promoter Pilichou et al. (2009)
Dg3 Desmoglein 3 Dsg2 Exon 4–6 Targeted deletion Krusche et al. (2011), Kant et al. (2012)
training (model Pg3; Kirchhof et al., 2006). Load reducing therapy
is able to prevent these symptoms of ARVC in Pg± mice (model
Pg4; Fabritz et al., 2011).
To circumvent the problem of neonatal lethality, a cardiac spe-
cific targeted deletion of Pg was developed under the control of
αMHCcre. Pgf/f αMHCcre (model Pg5) mice have ∼30% of the
WT protein as measured by Western blot, no Pg was detectable
by immunofluorescence on cardiac sections. Phenotypically these
mice largely recapitulate the human ARVC phenotype: cardiac
sudden death, progressive dilation, and fibrosis in the cardiac walls
(both in the left and the right ventricle) from 2 month onward. No
cardiac fat deposition was observed. With transmission electron
microscopy the structure of the desmosomes seemed to be dis-
rupted: other desmosomal proteins (e.g., Dsg2) appeared to be
absent from the intercalated disk (Li et al., 2011). Cell death in the
Pgf/f αMHCcre mice was at least partially through myocyte apop-
tosis in addition to myocyte necrosis in contrast to mice overex-
pressing N271S-Dsg2, which mainly showed myocyte necrosis (see
below; Pilichou et al., 2006; Li et al., 2011). Interestingly, increased
β-catenin staining was observed at the intercalated disk suggest-
ing partial rescue by this close relative of Pg (γ-catenin). To test
whether the lack of fast spontaneous death in these mice (model
Pg5) was due to a partial rescue by β-catenin, double-targeted mice
were created, carrying both a floxed Pg gene and a floxed β-catenin
locus (Pgf/f; β-cateninf/f). Crossing with αMHC/MerCreMer mice
and subsequent tamoxifen injections effected specific targeted
deletion. Double-targeted mice (model Pg6) showed a strong
arrhythmogenic phenotype, with 100% of the double-targeted
animals dying of sudden cardiac death between 3 and 5 months
after tamoxifen injections. In contrast to either single targeted
deletion and wild type littermates of which 4–9% died within
6 months of tamoxifen injection (Swope et al., 2012).
Two lines overexpressing wild type (model Pg7) and mutant
(model Pg8) Pg were generated (Lombardi et al., 2011); both
showed similar levels of increased incidence of sudden cardiac
death, an indication that even moderate levels of overexpression
of Pg disturb the balance of the mechanical interaction and sig-
naling functions of Pg independent of the introduced truncating
mutation.
DESMOPLAKIN TARGETED DELETION AND
OVEREXPRESSION MODELS
Desmoplakin (Dsp) targeted deletion mice Dsp−/− die at embry-
onic day 6.5 of malformations in the extra-embryonic tissue before
assessment of a cardiac phenotype is possible (Gallicano et al.,
1998). To overcome this problem the extra-embryonic phenotype
was rescued by tetraploid aggregation (model Dp1). The result-
ing embryos die around embryonic day E11. At E10 they show
severe cardiac malformation although desmosomal-like structures
appear to be present by transmission electron microscopy. As these
mice die well before birth they are obviously unsuitable as a proper
model for ARVC (Gallicano et al., 2001). The embryonic lethality
of the Dsp−/− mice is partially circumvented in the cardiac spe-
cific, αMHCcre induced, targeted deletion of Dsp (model Dp2;
Garcia-Gras et al., 2006). The homozygous cardiac specific dele-
tion of Dsp leads to embryonic growth arrest at day E10–E12 with
embryos that appeared very pale, with no circulating red blood
cells in organs. The heart was poorly formed with no chamber
specification, 80% of Dsp−/− mice did not survive until delivery.
Mice that did survive the embryonic period died within 6 weeks
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after birth. HeterozygousDsp±mice developed normally, however
adult Dsp± mice had thin ventricular walls, increased left ven-
tricular diameters and reduced left ventricular ejection fraction.
Spontaneous arrhythmias were observed on surface ECG and 4/5
mice developed ventricular arrhythmias after a single ventricular
extra stimulus.
A more detailed study of these Dsp± mice at earlier stages of
disease development, when no abnormalities at the surface ECGs
could be detected and no evidence of replacement fibrosis could
yet be found, showed a significant increase in the activation time
and inducible arrhythmias in Langendorff perfused hearts. These
results indicate the presence of electrophysiological abnormalities
before the onset of overt structural changes (Gomes et al., 2012).
However, no electron microscopy was done to exclude the presence
of disrupted desmosomes at the ultrastructural level.
Transgenic mice with cardiac overexpression of flag tagged
human Dsp cDNA both wild type (WT-Tg, model Dp3) and with
a C-terminal mutation (R2834H-Tg, model Dp4) were generated
by Yang et al. (2006). Overexpression of Dsp with N-terminal
mutations, e.g., V30M (model Dp5) and Q90R (model Dp6) led
to embryonic lethality after embryonic day 13.5 due to reduced
ventricular wall thickness and ventricular dilatation. R2834H-Tg
mice had an increased heart weight/body weight ratio compared
to both wild type littermates and Wt-Tg mice. R2834H-Tg hearts
showed increased apoptosis and fibrosis along with reduced ven-
tricular function and dilatation of both right and left ventricles.
Co-immunoprecipitation indicated the disruption of the interac-
tion between Dsp and Pg. at the ultrastructural level widening of
the intercalated disk was observed in Dp4 mice.
DESMOGLEIN OVEREXPRESSION MODELS
Transgenic mice with cardiac overexpression of flag tagged Dsg2
both wild type (Tg-WT,model Dg1) and N271S-Dsg2 mutant (Tg-
NS, model Dg2) were generated; the murine N271S mutation is
the mouse homolog of the human ARVC mutation DSG2–N266S.
While mice overexpressing of wild type Dsg2 were indistinguish-
able from their wild type littermates at 2 months of age, Tg-Ns
mice developed spontaneous ventricular arrhythmias, conduction
slowing, ventricular dilatation and aneurysms, and replacement
fibrosis, leading to sudden cardiac death from a less than 2 weeks
of age. The disease process was triggered by myocyte necrosis fol-
lowed by calcification and fibrous tissue replacement (Pilichou
et al., 2009). These findings are consistent with the results obtained
in mice carrying a targeted deletion in the extracellular adhe-
sion domain of Dsg2 (model Dg3). Approximately 30% of the
mice homozygous for the mutation survived embryonic devel-
opment. These mice develop left and right ventricular dilatation,
fibrosis, calcification, and spontaneous death similar to the Tg-NS
mice (Krusche et al., 2011). Detailed investigation of this model
by transmission electron microscopy revealed a widening of the
intercellular space at the intercalated disk and loss of desmosomal
structure close to macroscopically visible lesions of the heart (Kant
et al., 2012).
DISCUSSION AND CONCLUSION
The diverse mouse models discussed here recapitulate ARVC dis-
ease phenotype and have led to several new insights in the etiology
of the cardiac phenotype in ARVC patients. The initial targeted
deletion of single desmosomal genes, although embryonically
lethal, gave fundamental insights in effects of desmosomal gene
dysfunction on cardiac function. All the different models surviv-
ing embryonic development, recapitulate the human phenotype
in the sense of the arrhythmogenicity, replacement fibrosis, and
calcification. None of the models show the clear fatty infiltrations
seen in human, this is most likely a reflection of the different
composition of the extracellular matrix and non-cardiomyocytes
interstitial cells in the wild type murine heart, which lacks a signif-
icant adipocyte population (Pilichou et al., 2009). In all described
mouse models that survive the embryonic period, the disease
process is triggered by cardiac cell death upon cardiac stress after
birth. However, they are inconsistent considering the type of cell
death occurring, with necrosis being the prominent feature in the
Desmoglein 2 models (Dg2 and Dg3) and apoptosis (in addi-
tion to necrosis) in the plakoglobin models (Pg5 and Pg6). As
a consequence of the myocyte death, calcification, and replace-
ment fibrosis occurs leading to reduced cardiac function and
ventricular dilatation. This scar formation also provides a sub-
strate for the arrhythmogenic phenotype seen both in human
patients and the ARVC mouse models. The study by Fabritz
et al. (2011) shows the positive effect of load reducing therapy
on disease progression, clearly underwriting the current disease
management strategy of discouraging strenuous physical exercise
in patients.
Knowledge of the early disease stages would help in designing
more effective treatments (Basso et al., 2011). However, the earli-
est phase of the disease remains thus far elusive due to the early
postnatal severe pathogenicity of the phenotype, precluding the
effective dissection of the first pathological changes in the affected
hearts. The recent study of Gomes et al. suggests the presence of an
electrophysiological disturbance before the development of overt
cardiomyopathic changes (Kaplan et al., 2004; Gomes et al., 2012).
The proposal of electrical disturbances at this early stage of the
disease is an attractive one in the light of the recent data showing
cross talk between the mechanical junctions, the gap junctions and
the Na+ channel complex (Sato et al., 2009, 2011) and the pres-
ence of arrhythmias early in the disease process in humans (Bauce
et al., 2005). Unfortunately, this study fails to examine the desmo-
somal structure at this specific time point; it would be interesting
to see whether there are ultrastructural changes present that cause
the observed electrical changes. Furthermore, the electrophysi-
ological data presented lacks sufficient detail (e.g., Na+-current
and action potential measurements) to be able to draw defin-
itive conclusions on the nature of the observed early electrical
disturbances.
In conclusion, since the discovery a little over a decade ago
that the cause of ARVC lies within the cardiac desmosomal
complex and its associated proteins, a wealth of knowledge has
been build up on the etiology of the disease. The use of the
murine transgenic and targeted models has played a pivotal role
in this process. The quest to answer the many remaining ques-
tions on the first stages of the disease and the search for a good
treatment will continue during the next decade, the developed
mouse models will undoubtedly play an important role in this
process.
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